Y Bai1, J Gao, W Zhang, D Zou, Z Li. 1. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Abstract
BACKGROUND: Several clinical trials evaluating the prophylactic effect of allopurinol on postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis have been published; however, there is no consensus on whether prophylactic allopurinol can reduce the incidence of post-ERCP pancreatitis. AIM: To compare prophylactic allopurinol with placebo on post-ERCP pancreatitis reduction by performing a meta-analysis in randomized controlled trials. METHODS: Databases including MEDLINE, EMBASE and the Cochrane Library, Science Citation Index were searched to find relevant trials. Two reviewers independently identified relevant randomized controlled trials assessing the effect of prophylactic allopurinol on the incidence of post-ERCP pancreatitis. Outcome measures were the incidence of post-ERCP pancreatitis. RESULTS: Four trials involving 1730 patients were included. Analysis suggested that post-ERCP pancreatitis rates were not significantly different (allopurinol 8.9%, placebo 9.7%, P = 0.68), RR 0.86 (95% CI: 0.42, 1.77). Subsequent subgroup analysis confirmed that allopurinol was not statistically superior to placebo in reducing post-ERCP pancreatitis. CONCLUSION: Based on current best evidence, prophylactic allopurinol may not be useful for post-ERCP pancreatitis reduction.
BACKGROUND: Several clinical trials evaluating the prophylactic effect of allopurinol on postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis have been published; however, there is no consensus on whether prophylactic allopurinol can reduce the incidence of post-ERCP pancreatitis. AIM: To compare prophylactic allopurinol with placebo on post-ERCP pancreatitis reduction by performing a meta-analysis in randomized controlled trials. METHODS: Databases including MEDLINE, EMBASE and the Cochrane Library, Science Citation Index were searched to find relevant trials. Two reviewers independently identified relevant randomized controlled trials assessing the effect of prophylactic allopurinol on the incidence of post-ERCP pancreatitis. Outcome measures were the incidence of post-ERCP pancreatitis. RESULTS: Four trials involving 1730 patients were included. Analysis suggested that post-ERCP pancreatitis rates were not significantly different (allopurinol 8.9%, placebo 9.7%, P = 0.68), RR 0.86 (95% CI: 0.42, 1.77). Subsequent subgroup analysis confirmed that allopurinol was not statistically superior to placebo in reducing post-ERCP pancreatitis. CONCLUSION: Based on current best evidence, prophylactic allopurinol may not be useful for post-ERCP pancreatitis reduction.
Authors: Elham Afghani; Stephen J Pandol; Tooru Shimosegawa; Robert Sutton; Bechien U Wu; Santhi Swaroop Vege; Fred Gorelick; Morihisa Hirota; John Windsor; Simon K Lo; Martin L Freeman; Markus M Lerch; Yoshihisa Tsuji; Gil Y Melmed; Wahid Wassef; Julia Mayerle Journal: Pancreas Date: 2015-11 Impact factor: 3.327
Authors: Gabriele Fluhr; Julia Mayerle; Eckhard Weber; Ali Aghdassi; Peter Simon; Thomas Gress; Thomas Seufferlein; Joachim Mössner; Andreas Stallmach; Thomas Rösch; Martina Müller; Britta Siegmund; Petra Büchner-Steudel; Ina Zuber-Jerger; Marcus Kantowski; Albrecht Hoffmeister; Jonas Rosendahl; Thomas Linhart; Jochen Maul; László Czakó; Péter Hegyi; Matthias Kraft; Georg Engel; Thomas Kohlmann; Anne Glitsch; Tilman Pickartz; Christoph Budde; Claudia Nitsche; Kirsten Storck; Markus M Lerch Journal: BMC Gastroenterol Date: 2013-01-15 Impact factor: 3.067
Authors: Sarah Müller; Hannah Kaiser; Burkhard Krüger; Brit Fitzner; Falko Lange; Cristin N Bock; Horst Nizze; Saleh M Ibrahim; Georg Fuellen; Olaf Wolkenhauer; Robert Jaster Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240